SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the month of September, 2018
Commission File Number 001-38079
UROGEN PHARMA LTD.
(Translation of registrants name into English)
9 HaTaasiya Street
Raanana 4365007, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On September 27, 2018, Arie Belldegrun, Chairman of the Board of Directors of UroGen Pharma Ltd. (the Company), exercised options to purchase 10,000 ordinary shares, par value NIS 0.01 per share (Shares), of the Company at an exercise price of $17.67 per share and exercised options to purchase 20,000 Shares of the Company at an exercise price of $43.67 per share.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|UROGEN PHARMA LTD.|
|September 28, 2018||By:|
|Chief Executive Officer|